China’s Centers for Disease Control (CDC) on Saturday for the first time acknowledged the low efficiencies of two state – owned COVID – 19 vaccines.
Gao Fu, the director of China’s CDC, said at a conference that two vaccines produced by Chinese companies Sinovac and Sinopharm “do not have very high protection rates”, the Associated Press reported while pointing out that the country Foreign Ministry says nearly two dozen countries have accepted the vaccines for distribution.
He also said officials are now considering approving other vaccines for distribution.
“It is now formally being considered whether we should use different vaccinations from different technical lines for the vaccination process,” he added, according to the AP.
The news service also reported that a second Chinese CDC official confirmed at a news conference on Sunday that officials were conducting clinical trials with vaccines that use the message RNA (mRNA) process for delivery, as opposed to the inactivated vaccines used by Sinovac. and Sinopharm was released. uses dead virus particles to stimulate immunity in patients.
“The mRNA vaccines developed in our country have also entered the clinical trial stage,” said second CDC official, Wang Huaqing, according to the AP.
China’s vaccination program has been criticized by some US officials accusing Beijing of using donations of the two companies’ vaccines around the world for diplomatic purposes, while falsely predicting the effectiveness of Chinese vaccines and the vaccinations provided by the mRNA process manufactured, downsized, including those manufactured by Pfizer and Moderna.
A study by Brazilian health officials released in January found that the Sinovac injection was just over 50 percent effective in preventing cases of COVID-19.
Sinopharm said its vaccine was 79 percent effective in preventing COVID-19 infections, while a study conducted in the United Arab Emirates found it to be 86 percent effective.